Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder

This is the authors' abstract. We don't add key points for this paper.

Acid peptic disorders are a group of disorders that include gastroesophageal reflux disease, gastric ulcer, and duodenal ulcer.The most common causes are nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection.If not treated adequately, it may lead to life-threatening complications like gastrointestinal bleeding and intestinal perforation.H + K + -ATPase enzyme in parietal cells is involved in the final step of gastric acid secretion through a conformational change from E 1 to E 2 form.Proton-pump inhibitors (PPIs) are commonly used drugs for the treatment of acid peptic disorders.Proton-pump inhibitors have some limitations such as irreversible inhibition, it is a prodrug.Continuous attempts are made to develop newer targets that overcome these limitations of PPIs in treating acid peptic disorders.Vonoprazan, a novel potassium-competitive acid blocker (P-CAB) approved by the FDA for H. pylori infection in combination with antibiotics, could be a potential alternative to PPI in the management of acid peptic disorders.This review mainly highlights the pharmacology of Vonoprazan.